Maxime Dely: Does Whole Blood Deserve a Greater Role in Modern Transfusion Medicine?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post onย LinkedIn:
”๐ฃ๐น๐ฎ๐๐บ๐ฎ, ๐ฝ๐น๐ฎ๐๐ฒ๐น๐ฒ๐๐, ๐ฟ๐ฒ๐ฑ ๐ฏ๐น๐ผ๐ผ๐ฑ ๐ฐ๐ฒ๐น๐น๐: ๐ฆ๐ต๐ผ๐๐น๐ฑ ๐๐ฒ ๐ธ๐ฒ๐ฒ๐ฝ ๐๐ฒ๐ฝ๐ฎ๐ฟ๐ฎ๐๐ถ๐ป๐ด… ๐ผ๐ฟ ๐๐๐ฎ๐ฟ๐ ๐ฟ๐ฒ๐๐ต๐ถ๐ป๐ธ๐ถ๐ป๐ด?
For decades, transfusion medicine has relied on a widely accepted principle: separating donated blood into components (red blood cells, plasma, platelets) to optimize each donation and target specific clinical needs.
๐๐ฉ๐ช๐ด ๐ฎ๐ฐ๐ฅ๐ฆ๐ญ ๐ฉ๐ข๐ด ๐ด๐ข๐ท๐ฆ๐ฅ ๐ฎ๐ช๐ญ๐ญ๐ช๐ฐ๐ฏ๐ด ๐ฐ๐ง ๐ญ๐ช๐ท๐ฆ๐ด โ ๐ฃ๐ถ๐ต ๐ช๐ด ๐ช๐ต ๐ด๐ต๐ช๐ญ๐ญ ๐ต๐ฉ๐ฆ ๐ฃ๐ฆ๐ด๐ต ๐ข๐ฑ๐ฑ๐ณ๐ฐ๐ข๐ค๐ฉ ๐ต๐ฐ๐ฅ๐ข๐บ?
In certain clinical settings โ trauma, surgery, ICU โ patients often receive all three components separately.
In effect, ๐๐ฒโ๐ฟ๐ฒ ๐ฟ๐ฒ๐ฎ๐๐๐ฒ๐บ๐ฏ๐น๐ถ๐ป๐ด ๐๐ต๐ผ๐น๐ฒ ๐ฏ๐น๐ผ๐ผ๐ฑ, at the cost of logistical complexity, higher costs, and sometimes increased transfusion-related risks.
Shortages, overtransfusion, component waste, and supply chain strain are all issues pushing practitioners to reassess.
In response, ๐บ๐ถ๐น๐ถ๐๐ฎ๐ฟ๐ ๐ฎ๐ป๐ฑ ๐๐ฟ๐ฎ๐๐บ๐ฎ ๐๐ฒ๐ฟ๐๐ถ๐ฐ๐ฒ๐ ๐ฎ๐ฟ๐ฒ ๐ฟ๐ฒ๐ถ๐ป๐๐ฟ๐ผ๐ฑ๐๐ฐ๐ถ๐ป๐ด ๐น๐ฒ๐๐ธ๐ผ๐ฟ๐ฒ๐ฑ๐๐ฐ๐ฒ๐ฑ ๐๐ต๐ผ๐น๐ฒ ๐ฏ๐น๐ผ๐ผ๐ฑ, which is simpler to store and administer, and often more physiologically effective in critical care scenarios.
At the same time, predictive tools, AI-based algorithms, and innovative products (customized components, artificial blood, freeze-dried plasma) are paving the way toward ๐บ๐ผ๐ฟ๐ฒ ๐ฝ๐ฒ๐ฟ๐๐ผ๐ป๐ฎ๐น๐ถ๐๐ฒ๐ฑ, ๐ฒ๐ณ๐ณ๐ถ๐ฐ๐ถ๐ฒ๐ป๐, ๐ฎ๐ป๐ฑ ๐๐ฎ๐ฟ๐ด๐ฒ๐๐ฒ๐ฑ ๐๐ฟ๐ฎ๐ป๐๐ณ๐๐๐ถ๐ผ๐ป ๐๐๐ฟ๐ฎ๐๐ฒ๐ด๐ถ๐ฒ๐.
So should we keep separating blood by default? Or tailor our practices to real-world needs, resource constraints, and clinical outcomes?
Rethinking doesn’t mean rejecting. It means ๐ฒ๐๐ผ๐น๐๐ถ๐ป๐ด ๐ฎ ๐ต๐ถ๐๐๐ผ๐ฟ๐ถ๐ฐ ๐บ๐ผ๐ฑ๐ฒ๐น toward greater agility, precision, and clinical relevance.
Whatโs your view? Does whole blood deserve a greater role in modern transfusion medicine?”
Stay informed with Hemostasis Today.
-
Aug 13, 2025, 06:44Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
-
Aug 13, 2025, 05:41ISTH 2025 Recorded Sessions Now Available on ISTH Academy
-
Aug 13, 2025, 01:39Radoslaw Kaczmarek: Challenges Limiting Gene Therapy Use in Hemophilia
-
Aug 12, 2025, 20:03David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
-
Aug 12, 2025, 18:44Maxime Dely: Does Whole Blood Deserve a Greater Role in Modern Transfusion Medicine?
-
Aug 13, 2025, 06:13Pip Nicolson: Understanding VITT From COVID-19 Vaccines
-
Aug 13, 2025, 05:23Baseline Hemoglobin Predicts Outcomes in Acute VTE: Low Hb Linked to Higher Bleeding, Ischemia and Mortality Risk
-
Aug 13, 2025, 04:13Lindsey George on Gene Therapy Transforming Hemophilia Care
-
Aug 13, 2025, 02:26Case Report Alert: Basilar Artery Occlusion in IgA-APS
-
Aug 12, 2025, 20:23Behnood Bikdeli on Comparative Effectiveness Research Examples in Thrombosis
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bรผcke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025
-
Aug 7, 2025, 14:49JAMA+AI Conversations: David Rhew's Journey from Clinical Practice to Technology Leadership
-
Aug 6, 2025, 16:47My Clot Story: Birth Control and A Life-threatening Pulmonary Embolism